Skip to main content

Table 2 Case-control study: preadmission statin use and risk of hospitalization for pneumonia in Denmark (1997-2009)

From: The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study

Statin use

Pneumonia cases

(n = 70,914)

Population controls

(n = 709,140)

Crudea OR

(95% CI)

Adjustedb OR

(95% CI)

Never

61,783 (87.1%)

630,515 (88.9%)

1.00 (reference)

1.00 (reference)

Former (>125 days before admission)

1,908 (2.7%)

14,102 (2.0%)

1.42 (1.35-1.50)

0.97 (0.91-1.02)

Current (≤125 days before admission)

7,223 (10.2%)

64,523 (9.1%)

1.17 (1.14-1.21)

0.80 (0.77-0.83)

Current (≤125 days before admission), supplementary adjusted model for 2001-2009

6,883 (13.0%)

61,450 (11.6%)

1.18 (1.15-1.21)

0.77 (0.74-0.80)

  1. aMatched for age, sex, urbanization of place of residence, and hospitalization/index date. bAdjusted for marital status, calendar period, living with small children, any recent surgical procedure, 20 different comorbidities, alcoholism-related conditions, and 18 different preadmission medications (Table 1). The supplementary model for 2001-2009 includes 53,160 pneumonia cases and 531,600 controls and is also adjusted for receipt of current year's influenza vaccine, dementia, social medicine-related consultations, application for reimbursement for chronic or terminal illness, conversational therapy, and general practitioner preventive consultations and services. CI, confidence interval; OR, odds ratio.